MedPath

Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR

Overview

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes. Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults. As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old. Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania. Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking. Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania. Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions

  • Acute Agitation
  • Bipolar 1 Disorder
  • Bipolar Disorder With Manic or Mixed Episodes
  • Delirium
  • Delusional Parasitosis
  • Depressive Episodes
  • Gilles de la Tourette's Syndrome
  • Major depressive disorder, recurrent episode
  • Mixed manic depressive episode
  • Post Traumatic Stress Disorder (PTSD)
  • Psychosis
  • Schizophrenia
  • Acute Manic episode

FDA Approved Products

Olanzapine
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/14
NDC:70518-0921
Olanzapine
Manufacturer:Proficient Rx LP
Route:ORAL
Strength:2.5 mg in 1 1
Approved: 2021/01/01
NDC:63187-453
Zyprexa
Manufacturer:Eli Lilly and Company
Route:ORAL
Strength:15 mg in 1 1
Approved: 2022/11/11
NDC:0002-4415
Olanzapine
Manufacturer:Proficient Rx LP
Route:ORAL
Strength:10 mg in 1 1
Approved: 2021/01/01
NDC:63187-429
Olanzapine
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:20 mg in 1 1
Approved: 2024/02/21
NDC:70518-1582

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath